Next Article in Journal
Assessing the Single and Combined Toxicity of Chlorantraniliprole and Bacillus thuringiensis (GO33A) against Four Selected Strains of Plutella xylostella (Lepidoptera: Plutellidae), and a Gene Expression Analysis
Next Article in Special Issue
Antidepressant-Like Properties of Intrastriatal Botulinum Neurotoxin-A Injection in a Unilateral 6-OHDA Rat Model of Parkinson’s Disease
Previous Article in Journal
Reduction of Ochratoxin A during the Preparation of Porridge with Sodium Bicarbonate and Fructose
Previous Article in Special Issue
Use of Botulinum Neurotoxin in Parkinson’s Disease: A Critical Appraisal
 
 
Review
Peer-Review Record

Therapeutic Applications of Botulinum Neurotoxin for Autonomic Symptoms in Parkinson’s Disease: An Updated Review

by Steven D. Mitchell * and Christos Sidiropoulos
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Submission received: 31 January 2021 / Revised: 17 March 2021 / Accepted: 17 March 2021 / Published: 19 March 2021
(This article belongs to the Special Issue Botulinum Neurotoxin and Parkinson’s Disease)

Round 1

Reviewer 1 Report

It is a useful review summarizing current evidence for the use of botulinum neurotoxins in treatments of Parkinson's disease. One caveat to address is to list in the Results table the types of BoNT used - type A or type B (or both) - in the Toxin type column. In addition, most of the next column listing number of patients consists of N/A which doesn't look presentable. The authors could add the few available numbers in another column.

Author Response

Please see the attachment

Author Response File: Author Response.pdf

Reviewer 2 Report

The article "Therapeutic applications of botulinum toxin type A in Parkinson's disease" is a well written informative short review of the recent literature. It also warns the readers on the possible novel indications in the e.g. treatment of movement disorders such as blepahrospasm which may be present in PD. The literature list is somewhat limited to the more recent reviews, rather than citing original clinical studies. Other than that I have no further comments.

Author Response

Please see the attachment

Author Response File: Author Response.pdf

Back to TopTop